D-Dimer Levels Up in C1-INH Deficient Hereditary Angioedema

This article originally appeared here.
D-Dimer Levels Up in C1-INH Deficient Hereditary Angioedema
D-Dimer Levels Up in C1-INH Deficient Hereditary Angioedema

(HealthDay News) — Elevated levels of plasma D-dimer are associated with attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor (C1-INH) deficiency (C1-INH-HAE), according to a study published online Jan. 30 in Allergy.

Avner Reshef, M.D., from the University of Tel Aviv in Israel, and colleagues conducted a phase III, randomized, placebo-controlled study to examine the safety of recombinant human C1INH (rhC1INH) for the treatment of acute attacks in 74 patients with C1-INH-HAE. Patients were monitored for thrombotic/thromboembolic events (TEEs) and assessment of deep vein thrombosis (DVT). Levels of fibrin degradation products (plasma D-dimers) were evaluated at baseline and at two hours and seven days post-treatment.

The researchers found that in 80 percent of the patients, plasma D-dimer levels were elevated, and they were higher in patients with submucosal versus subcutaneous attacks. At baseline and at two hours post-infusion, the median plasma D-dimer levels were comparable across treatment groups. By day seven, median plasma D-dimer levels decreased in both groups. There was no increased risk of DVT, nor any TEEs, reported with rhC1INH treatment or control.

"Elevated plasma D-dimer levels were associated with acute C1-INH-HAE attacks, particularly with submucosal involvement," the authors write. "However, rhC1INH therapy was not associated with thrombotic events."

Several authors disclosed financial ties to the pharmaceutical and technology industries.

Abstract
Full Text (subscription or payment may be required)

Loading links....